New Herceptin biosimilar under EMA review
Following in the footsteps of Celltrion (Kosdaq: 068270), Samsung Bioepis, Amgen (Nasdaq: AMGN) and others, Prestige BioPharma is making headway with its Herceptin (trastuzumab) biosimilar.
The Singapore-based company has had its marketing authorization application (MAA) approved by the European Medicines Agency (EMA), giving it the chance of reaching a major market with a copy of the Roche (ROG: SIX) drug, which is indicated for HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Prestige’s Phase I/III data on its HD201 candidate includes results showing exceptional biosimilarity to Herceptin in terms of clinical response and pharmacokinetics, and a comparable safety profile to the range previously observed in Herceptin biosimilar trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze